New Oral Drug Infigratinib Shows Significant Growth Improvement in Children with Achondroplasia
A phase 3 trial published in NEJM reveals infigratinib, an oral medication, significantly boosts growth in children with achondroplasia compared to placebo. This marks a potential leap forward, offering a more convenient treatment option than current injections, especially for early intervention.